138 related articles for article (PubMed ID: 17926208)
1. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
Bender S; Flicker L; Rhodes R
Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
[No Abstract] [Full Text] [Related]
2. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
3. Access to medication and drug company sales practices: setting priorities for critique and advocacy.
Seiler N
Am J Bioeth; 2003; 3(3):61. PubMed ID: 14594498
[No Abstract] [Full Text] [Related]
4. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
Schüklenk U; Lowry C
Br Med Bull; 2009; 89():7-22. PubMed ID: 19056723
[TBL] [Abstract][Full Text] [Related]
5. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
6. Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
Allen MC
Spec Law Dig Health Care Law; 1998 Dec; (236):9-29. PubMed ID: 10187553
[No Abstract] [Full Text] [Related]
7. Avoiding legal and ethical pitfalls of industry-sponsored research: the co-existence of research, scholarship, and marketing in the pharmaceutical industry.
Dorfman HL; Reig LP
Food Drug Law J; 2004; 59(4):595-615. PubMed ID: 15880876
[No Abstract] [Full Text] [Related]
8. Cancer, access to investigational drugs, and patient rights in the U.S.A. and India.
Sheehan HE
Indian J Med Ethics; 2008; 5(4):170-2; discussion 173. PubMed ID: 18988376
[No Abstract] [Full Text] [Related]
9. The proper focus for FDA regulations: why the fundamental right to self-preservation should allow terminally ill patients with no treatment options to attempt to save their lives.
Puckett A
SMU Law Rev; 2007; 60(2):635-65. PubMed ID: 17849632
[No Abstract] [Full Text] [Related]
10. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
11. Causes for concern and causes of action: a comment on "Pushing drugs".
Brownsword R
Washburn Law J; 2003; 42(3):601-14. PubMed ID: 15115002
[No Abstract] [Full Text] [Related]
12. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
13. Freebies for subject 641: a discussion of the ethical prospect of providing drug trial subjects with post-trial access to the drug tested--a Canadian perspective.
Hutt LE
Health Law J; 1998; 6 Spec No():169-87. PubMed ID: 14746066
[TBL] [Abstract][Full Text] [Related]
14. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
15. Access to investigational drugs in the USA.
Lancet; 2007 Aug; 370(9587):540. PubMed ID: 17707730
[No Abstract] [Full Text] [Related]
16. Expanding access to investigational new therapies.
Cohen C; Shevitz A; Mayer K
Prim Care; 1992 Mar; 19(1):87-96. PubMed ID: 1594704
[TBL] [Abstract][Full Text] [Related]
17. Regulating manufacturer-affiliated communication in the information age.
Schulman KA; Abernethy DR; Rathore SS; Woosley RL
Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
[No Abstract] [Full Text] [Related]
18. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Schultheis LW; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
[No Abstract] [Full Text] [Related]
19. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
Orlando VI
Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
[No Abstract] [Full Text] [Related]
20. Should terminally ill patients have access to phase I drugs?
Bristol N
Lancet; 2007 Mar; 369(9564):815-6. PubMed ID: 17366691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
